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ARF encodes a potent tumor suppressor that antagonizes MDM2, a negative regulator of p53. ARF also
suppresses the proliferation of cells lacking p53, and loss of ARF in p53-null mice, compared with ARF or p53
singly null mice, results in a broadened tumor spectrum and decreased tumor latency. To investigate the
mechanism of p53-independent tumor suppression by ARF, potential interacting proteins were identified by
yeast two-hybrid screen. The antiapoptotic transcriptional corepressor C-terminal binding protein 2 (CtBP2)
was identified, and ARF interactions with both CtBP1 and CtBP2 were confirmed in vitro and in vivo.
Interaction with ARF resulted in proteasome-dependent CtBP degradation. Both ARF-induced CtBP degra-
dation and CtBP small interfering RNA led to p53-independent apoptosis in colon cancer cells. ARF induction
of apoptosis was dependent on its ability to interact with CtBP, and reversal of ARF-induced CtBP depletion
by CtBP overexpression abrogated ARF-induced apoptosis. CtBP proteins represent putative targets for
p53-independent tumor suppression by ARF.
ARF (p19ARF in mouse [mArf] and p14ARF in human
[hARF]) is a tumor suppressor product of the INK4a/ARF
locus (34) that acts, in part, by stabilizing p53 (reviewed in
reference 40). Germ line homozygous knockout of Arf in mice
results in the development of highly penetrant lymphoma or
sarcoma, a phenotype similar to that observed with p53-defi-
cient mice (22, 39). Given the molecular observation that ARF
stabilizes and activates p53 by antagonizing MDM2, ARF in-
activation has been commonly viewed as one of many means of
inactivating the p53 pathway, a sine qua non for mammalian
tumorigenesis (27). Accordingly, ARF is frequently inactivated
in human cancers by deletion, mutation, or transcriptional
silencing (38). However, the finding of simultaneous p53 and
INK4a/ARF inactivation in certain human tumors suggests
that ARF may encode an additional tumor suppressor func-
tion(s) apart from the activation of p53 (35).
Given the difficulty of distinguishing the tumor suppressor
contributions of the often concordantly regulated p16INK4a and
ARF genes in humans (38), analysis of Arf-specific knockout
mice has provided additional evidence for p53-independent
functions of ARF. Epithelial tumors are rare in p53 knockout
mice but, depending on the study, are observed in about 12%
to 28% of Arf knockout mice (21, 39). Further loss of p53
and/or the p53 and ARF antagonist Mdm2 results in a sub-
stantially increased incidence of epithelial cancers, including
those of the digestive tract (31, 48). In comparison, mice with
loss of p53 and Mdm2 but retention of Arf display mainly
mesenchymal tumors, as do p53 knockout mice (19, 30, 48).
Moreover, in a transgenic K-ras skin cancer model, Arf loss
accelerated tumor growth in a p53-independent manner (24).
Thus, the genetic evidence in the mouse supports the existence
of an ARF tumor suppressor activity that functions indepen-
dently of p53.
At the cellular level, ARF can suppress the proliferation of
p53-defective cells (48, 52). At least two mechanisms have
been identified. First, under conditions of overexpression,
ARF appears to bind and antagonize both c-myc and activator
E2F proteins, the latter also being degraded via the protea-
some, thus slowing progression of cells through the G1/S tran-
sition and decreasing proliferative rate (10, 11, 28, 33). Second,
ARF is concentrated in nucleoli, forming a stoichiometric
complex with nucleophosmin/B23, disrupting ribosome bio-
genesis by interfering with the export of rRNA (2, 4, 18, 25,
41). This, in turn, would be predicted to hamper progression of
cells through the growth phases of the cell cycle.
The actual mechanism by which ARF affects the function of
interacting proteins remains unclear, though the functional
consequence is invariably inactivation (27). For some ARF
targets, ARF interaction can cause major alterations in meta-
bolic stability, as E2F1 and B23/nucleophosmin are destabi-
lized by proteasome degradation when complexed with ARF
(18, 28). Other targets display changes in modification or lo-
calization: MDM2 and B23 become sumoylated (42, 51),
MDM2 nuclear export is blocked (44), and E2Fs, c-myc, and
MDM2 are relocalized to the nucleolus (10, 28, 33, 49) upon
ARF expression.
Given that the known targets for p53-independent ARF
tumor suppression have yet to be precisely assigned to any
specific physiologic context related to tumor suppression, we
have attempted to identify additional cellular targets of ARF
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function. By use of a two-hybrid screen, the C-terminal binding
protein 2 (CtBP2) transcription regulator was identified as an
ARF-binding protein, and ARF interaction caused CtBP deg-
radation by the proteasome. Either ARF expression or CtBP-
specific small interfering RNA (siRNA) resulted in apoptosis
in p53-null colon cancer cells that was dependent on ARF/
CtBP interaction and depletion of cellular CtBP levels.
MATERIALS AND METHODS
Yeast two-hybrid screen. The mouse cDNA encoding full-length ARF was
cloned as an NcoI-PstI fragment into pGBKT7, in frame with the GAL4 DNA-
binding domain (DBD) (Clontech). A human testis cDNA library in the pACT2
GAL4 activation domain yeast expression vector was obtained from Clontech.
For library screening, the Saccharomyces cerevisiae reporter strain AH109 (Trp
Leu His Ade) was simultaneously transformed with the plasmid pGBKT7/
ARF and the cDNA library. The transformed yeast cells were selected by growth
on SD dropout medium (Ade His Leu Trp) in the presence of X-Gal
(5-bromo-4-chloro-3-indolyl--D-galactopyranoside). The interacting cDNA-de-
rived plasmids were recovered from yeast by reintroduction into Escherichia coli,
and the identities of putative interacting proteins were determined by sequencing
and BLAST search of the NCBI database.
Cell culture and transfections. Mouse embryo fibroblasts (MEFs) (wild type
[wt], ARF null, or p53 null) and human U2OS cells were cultured in complete
Dulbecco’s modified Eagle’s medium (DMEM). Human colon cancer (HCT116)
cells (ARF silenced) were grown in McCoy’s medium. Medium was supple-
mented with 10% fetal bovine serum-100 U/ml penicillin and incubated in hu-
midified 5% CO2 at 37°C. Expression plasmids were transfected using Fugene
(Roche), and siRNA duplexes were transfected with Oligofectamine (Invitro-
gen), with an siRNA concentration of 40 nM. siRNA sequences for human CtBP
(hCtBP) were as follows: AAACGACUUCACCGUCAAGCA for CtBP1 and
AAGCGCCUUGGUCAGUAAUAG for CtBP2.
Plasmid constructions. Full-length CtBP2 was cloned from human lung car-
cinoma cDNA by use of pcDNA3.1 (Invitrogen), directional TOPO cloning, and
specific sense (CACCATGGCCCTTGTGGATA) and antisense (TTGCTCGTT
GGGGTGCTC) primers. CtBP2 fragments were inserted in PET 44b (Novagen)
at BamHI and HindIII sites. CtBP deletion mutants were constructed in
pcDNA3.1 by use of specific PCR primers. The integrity of the plasmids was
confirmed by sequencing. pCD-mArf was generated by insertion of a PCR-
amplified mArf coding sequence into pCDNA3. Missense and deletion mArf
mutants were generated using PCR per the QuikChange protocol (Stratagene).
A synthetic mArf gene with arginine codons recoded and optimized for bacterial
usage was synthesized from overlapping oligonucleotides and PCR amplified
prior to cloning into BamHI/EcoRI sites of pGEX2tk.
Antibodies and Western blotting. Antibodies used were as follows: CtBP1
and CtBP2 (BD Transduction Laboratories), p19ARF (ab80; AbCam), p14ARF
(AbCam), glutathione S-transferase (GST) (Z-5; Santa Cruz), V5 tag (Invitro-
gen), hemagglutinin (HA) (12CA5; Roche), glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) (Advanced Immunochemical Inc.), S tag (Novagen),
poly(A-ribosyl) polymerase (PARP) (BD Pharmingen), and cleaved caspase 3
(Cell Signaling). Anti-rabbit immunoglobulin G (IgG)–horseradish peroxidase
and anti-mouse IgG–horseradish peroxidase conjugates (Amersham) were used
with ECL detection (Amersham) for Western blotting.
GST pulldown assays. GST-mArf (codons optimized for E. coli) and GST
were expressed in BL21. Lysates from U2OS cells transiently transfected with
full-length CtBP and mutants were prepared as described previously (5) and
incubated with GST or GST-conjugated mArf immobilized on glutathione-
Sepharose beads. The beads were washed with wash buffer (10 mM Tris [pH 8.0],
150 mM NaCl, 0.1% Triton X-100, 2 mM MgCl2, 10 M ZnCl2, 10% glycerol)
three times. Protein bound to beads was eluted with 20 mM glutathione in
elution buffer (10 mM Tris [pH 8.0], 120 mM NaCl, 0.1% Triton X-100, 10%
glycerol), separated by sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE), and immunoblotted.
S-tag affinity binding assay. CtBP2 mutants expressed in BL21 cells as S-tag
fusions in PET vector (Novagen) according to the manufacturer’s instructions
were incubated with S-protein agarose at 4°C for 1 h. Unbound proteins were
washed three times with wash buffer. Lysates from mArf-transfected U2OS cells
were incubated with CtBP bound to S-protein agarose at 4°C for 2 h. After the
beads were washed three times with wash buffer, the bound protein was released
by incubation of the agarose beads in 3 M MgCl2 for 10 min at room tempera-
ture, which was followed by immunoblotting of released proteins for ARF.
Coimmunoprecipitations. Cell lysates (100 g of protein) from 1.5  107 cells
in lysis buffer (20 mM HEPES, 10 M ZnCl2, 1 mM MgCl2, 250 mM NaCl, 0.1%
Triton X-100, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride [PMSF],
10 g/ml aprotinin and leupeptin) were incubated at 4°C for 1 h with specific
antibody-conjugated Sepharose used for immunoprecipitation. Beads were
washed three times in wash buffer (20 mM HEPES, 10 M ZnCl2, 1 mM MgCl2,
150 mM NaCl, 0.1% Triton X-100, 1 mM PMSF, 10 g/ml aprotinin and leu-
peptin), followed by SDS-PAGE and Western blotting.
UV irradiation. Cells (MEFs and U2OS) were grown to 60% confluence in
DMEM with supplements. The medium was removed, and the dishes were
exposed to 254-nm UV light (UV-C) at a dose of 0 to 30 J/m2 by use of a
Stratalinker (Stratagene). The cells were collected 6 h posttreatment, washed
with phosphate-buffered saline (PBS), and scraped in lysis buffer supplemented
with protease inhibitors. The lysates were then analyzed by Western blotting.
Adenoviral infections. Recombinant hARF (Ad-hARF)- and LacZ (Ad-
LacZ)-expressing adenoviruses (52) were the generous gift of T. Kowalik. Cells
(106) were plated in 6-well plates 24 h before infection at a confluence of 50%.
Cells were washed with PBS once and infected with the Ad-LacZ or Ad-hARF
virus in serum-free medium at a multiplicity of infection of 100 at 37°C for 1 h.
Virus medium was removed, McCoy’s medium was then added, and the cells
were incubated for 24 h prior to harvest.
Immunofluorescence. U2OS cells on coverslips were transfected with the in-
dicated mArf and V5-CtBP2 constructs, and 24 h after transfection, cells were
fixed and immunostained with anti-CtBP2 and anti-mArf antibodies (AEC40)
and anti-rabbit IgG–rhodamine as described previously (28).
[35S]methionine labeling pulse-chase analysis. HCT116 p53/ cells were
infected with Ad-LacZ or Ad-hARF and 24 h later were pulse-labeled for 60 min
with [35S]methionine (200 Ci/ml; Perkin Elmer) and then chased for various
times. The cells were then washed in PBS and lysed with 20 mM HEPES, 10 M
ZnCl2, 1 mM MgCl2, 250 mM NaCl, 0.1% Triton X-100, 1 mM dithiothreitol, 1
mM PMSF, and 10 g/ml aprotinin and leupeptin. For immunoprecipitations,
cell lysates (100 g of protein) were incubated at 4°C for 2 h with CtBP2
antibody-conjugated Sepharose, and beads were washed three times in wash
buffer (20 mM HEPES, 10 M ZnCl2, 1 mM MgCl2, 150 mM NaCl, 0.1% Triton
X-100, 1 mM PMSF, 10 g/ml aprotinin and leupeptin), followed by SDS-PAGE.
Gels were then dried, exposed to Kodak Biomax XAR film, and quantitated by
densitometry.
Cell cycle and apoptosis analysis. For cell cycle analysis of cells expressing
mArf, 106 3T3-D1 cells (32) were transfected with 5 g of pCD-mArf plasmid
plus 0.5 g plasmid encoding membrane-targeted green fluorescent protein
(GFP). Forty-eight hours after transfection, cells were trypsinized, washed once
in cold PBS, fixed in 5 ml cold methanol (20°C) for 30 min, centrifuged, and
resuspended in 0.5 ml PBS containing RNase A (50 g/ml) and propidium iodide
(100 g/ml). The cells were then subjected to flow cytometric analysis with gating
for GFP. For each sample, 5,000 GFP-positive cells were collected and cell cycle
distribution was analyzed according to relative DNA content. For viability anal-
ysis, cells were trypsinized and mixed 1:1 with trypan blue solution (0.8 mM in
PBS) and counted with a hemacytometer. An annexin V-PE apoptosis detection
kit (where PE is phycoerythrin) from BD Pharmingen was used according to the
manufacturer’s instructions to identify cells undergoing apoptosis. A Caspa Tag
Caspase-3/7 in situ assay kit (Chemicon International) was used for in situ
detection of activated caspases 3 and 7 by fluorescence-activated cell sorter
(FACS) analysis.
RESULTS
Two-hybrid screen for ARF-interacting proteins. To identify
ARF-interacting proteins that might explain the p53-indepen-
dent effects of ARF, a two-hybrid screen using mArf as bait
was performed against prey cDNAs derived from a human
testis cDNA library. A C-terminal fragment (residues 224 to
445) of hCtBP2 was identified in 4 of 12 colonies. CtBP pro-
teins are transcriptional corepressors with a protein interaction
domain near their N termini that recognizes a PLDLS se-
quence, an NADH-binding central dehydrogenase regulatory
domain, and a C-terminal PDZ-binding domain (Fig. 1A) (9).
The N-terminal PLDLS interaction domain was excluded from
the portion recovered in the two-hybrid screen. On rescreen,
by use of a GAL4 upstream activation sequence-LacZ reporter
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and an -galactosidase assay, hCtBP2 was found to interact
strongly with the GAL4 DBD fusion to mArf but not with the
GAL4 DBD alone, indicating that the interaction occurred
specifically through the ARF portion of the GAL4 DBD-mArf
fusion protein.
ARF and CtBP interact in vitro. To further characterize the
putative ARF/CtBP interaction, purified GST or GST-mArf
fusion proteins were incubated with U2OS cell lysates (Fig.
1B). GST-mArf, but not GST, was able to specifically recog-
nize the endogenous 48-kDa hCtBP2 protein from U2OS cell
lysates, suggesting that these proteins can specifically interact
both in yeast and in vitro.
In an effort to map the binding of mArf to hCtBP2, V5-tagged
full-length (V5-hCtBP2-FL), N-terminal (residues 1 to 321) [V5-
hCtBP2(1–321)], and C-terminal (residues 322 to 445) [V5-
hCtBP2(322–445)] constructs of hCtBP2 were transiently ex-
pressed in U2OS cells, followed by analysis for binding of the
V5-hCtBP2 proteins to purified GST versus GST-mArf. Consis-
tent with the yeast two-hybrid data, V5-hCtBP2-FL and V5-
hCtBP2(322–445), but not V5-hCtBP2(1–321), bound specifi-
cally to GST-mArf (Fig. 1C).
Likewise, mArf expressed in U2OS cells bound to S-tagged
C-terminal (residues 224 to 445) [S-CtBP2(224–445)] but not
S-tagged N-terminal (residues 1 to 350) [S-CtBP2(1–350)]
hCtBP2 fusion proteins produced in E. coli (Fig. 1D). More-
over, ARF is highly basic and thus prone to nonspecific pro-
tein-protein interactions (50). The lack of detectable mArf
binding to V5-hCtBP2(1–321) or S-CtBP2(1–350), which were
produced in different systems and tested against bacterially or
eukaryotically synthesized mArf, strongly suggests that ARF
interaction with the CtBP C terminus is specific.
ARF interacts with CtBP in vivo. To determine whether
ARF/CtBP interaction could be observed in cells and whether
it is regulated by cellular stress, such as UV exposure, U2OS
cells were transfected with V5-hCtBP2 and full-length mArf
expression vectors, followed by UV or mock irradiation. Trans-
fected cell lysates were then immunoprecipitated with anti-V5,
anti-ARF, or control anti-ras antibody, followed by immuno-
FIG. 1. ARF interacts with CtBP. (A) Schematic representation of CtBP functional domains and the ARF binding region at the C terminus,
as identified by a two-hybrid screen. The HIPK2 phosphorylation (P) site (S428) is noted. (B) CtBP interacts with ARF in vitro. GST or GST-mArf
fusion proteins were conjugated to glutathione-agarose beads and incubated with U2OS cell lysates. Bound, endogenous CtBP2 was assayed by
Western blotting. Input lane shows 10% of the cell lysate. GST and GST-mArf migration positions are indicated by arrows. (C) The CtBP C
terminus interacts with ARF. V5-tagged full-length (Fl), N-terminal (1–321), and C-terminal (322–445) hCtBP2 proteins were expressed in U2OS
cells. Binding of V5-hCtBP2 proteins to GST versus GST-mArf was assayed by immunoblotting of GST pulldowns. Arrows indicate the migration
positions of the wild type and deletion mutants of V5-hCtBP2 as well as GST-mArf. (D) The CtBP C terminus interacts with ARF. S-tagged
C-terminal (224–440) or N-terminal (1–350) hCtBP2 fusion proteins or unfused S-tag protein were expressed in E. coli, purified with S-protein
agarose, and incubated with a lysate of mArf-expressing U2OS cells. Bound mArf and the presence of S-tag fusion proteins were determined by
immunoblotting.
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FIG. 2. In vivo ARF interaction with CtBP. (A) Exogenous CtBP interacts with exogenous ARF in transfected cells. U2OS cells were
transfected with V5-hCtBP2 and mArf expression plasmids and UV or mock irradiated (10 J/m2) 24 h after transfection. Six hours after UV
exposure, cell lysates were immunoprecipitated with anti-ras (control), anti-ARF, or anti-V5 antibody, followed by Western blot analysis with
anti-V5, anti-CtBP1, or anti-ARF antibody. Input lane depicts 10% of the transfected cell lysate. (B) hARF interacts with CtBP. U2OS cells were
transfected with V5-hCtBP2 and myc-hARF expression plasmids. Immunoprecipitation was performed with V5 or control antibody (Ab), followed
by immunoblotting for hARF and V5. (C) (Middle and right panels) In vivo coimmunoprecipitation of mArf and mCtBP2 from lysates of wt,
p53-null, or p53/mArf-null MEFs. Immunocomplexes were analyzed for the presence of endogenous ARF and mCtBP2 by Western blotting. (Left
panel) 10% of input protein lysates. (D) CtBP2 and hARF colocalize. U2OS cells were transfected with hARF, V5-CtBP2, or both expression
plasmids. Twenty-four hours after transfection, cells were immunostained with rabbit anti-hARF and mouse anti-hCtBP2 antibodies, followed by
detection with fluorescein isothiocyanate-labeled (anti-rabbit) or rhodamine-labeled (anti-mouse) secondary antibody. Arrows indicate cells that
were transfected, as noted by a CtBP2 level increased above that seen with adjacent untransfected cells. The merged image highlights relocalization
of CtBP2 to nuclear bodies consistent with nucleoli, where hARF is found. Asterisks indicate untransfected cells.
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blotting with V5 and ARF antibodies. The negative control,
anti-ras antibody immunoprecipitate (IP), was clear of ARF,
V5-hCtBP2, and hCtBP1 (Fig. 2A). ARF was evident in the
anti-V5 IPs, and V5-hCtBP2 was detected in the anti-ARF IPs
(Fig. 2A, UV), consistent with a specific ARF/CtBP interac-
tion in vivo, though UV irradiation had no impact on binding
(Fig. 2A, UV).
To investigate whether ARF interacts with the highly similar
CtBP1 protein (23), the V5 and ARF IPs were also probed for
the presence of hCtBP1. Cellular hCtBP1 was detected in the
ARF IP but not in the V5 IP, suggesting that it also interacts
with ARF and that its presence in the ARF IP was not due to
oligomerization with exogenous V5-hCtBP2 protein (Fig. 2A).
Similarly to mArf, exogenously expressed myc-tagged hu-
man ARF protein (myc-hARF) was present in an anti-V5 IP,
but not a control IP, of a cell lysate derived from U2OS cells
cotransfected with myc-hARF and V5-hCtBP2 expression
plasmids (Fig. 2B), suggesting that both hARF and mArf in-
teract with CtBP.
To confirm that ARF and CtBP form an endogenous phys-
iologic complex in mammalian cells, lysates from MEFs that
were wt, null for p53, or null for both p53 and ARF were
immunoprecipitated with either anti-CtBP2 or anti-ARF anti-
body. ARF was more abundant in p53-null MEFs, as expected,
due to loss of p53 negative feedback on ARF expression (16)
(Fig. 2C). ARF coimmunoprecipitated with CtBP2, and vice
versa, when protein extracts were prepared from wild-type and
p53-null MEFs (Fig. 2C, second and third lanes of each panel).
The higher efficiency of the coimmunoprecipitate in p53-null
cell lysates reflected, in part, the greater baseline abundance of
ARF. A further effect of p53 loss on the avidity of mArf/CtBP2
interaction is also possible, as the increase in the amount of
bound mArf in the CtBP IP between wt and p53-null MEFs
was substantially greater than the observed difference in ex-
pression level of mArf between the two cell types. Cell lysates
from ARF-null cells were negative for ARF/CtBP2 coimmuno-
precipitation, demonstrating that detection of CtBP2 in the
ARF IP required the specific presence of ARF protein and
that the putative ARF immunoblot signal in the CtBP IPs was
also dependent on the presence of ARF in the cell lysates (Fig.
2C, first lane of each panel).
ARF relocalizes CtBP to the nucleolus. To further investi-
gate the physiologic significance of CtBP and ARF biochemi-
cal interaction, HCT116 p53/ cells were transfected with
V5-CtBP2 and vector or hARF expression plasmids, followed
by staining with anti-hARF and CtBP2 antibodies (Fig. 2D).
CtBP2 was exclusively nucleoplasmic in transfected or untrans-
fected cells and was excluded from unstained nuclear struc-
tures consistent with nucleoli (Fig. 2D, first panel). Conversely,
hARF displayed its typical nucleolar staining pattern (Fig. 2D,
second panel) (26, 50, 55), and its coexpression with CtBP2
resulted in nearly quantitative relocalization of CtBP2 into the
same subnuclear structures as hARF (Fig. 2D, third and fourth
panels). Consistent with the hARF dependence of CtBP2 re-
localization, cells within the same culture that did not express
exogenous CtBP2 and hARF retained the normal nucleoplas-
mic and nucleolar-excluded localization of CtBP2 (Fig. 2D,
third panel).
A conserved hydrophobic domain of ARF recognizes CtBP.
In order to identify the region of ARF required for CtBP
interaction, lysates of U2OS cells transfected with wild-type or
mutant mArf expression plasmids were immunoprecipitated
with hCtBP2 antibodies, followed by analysis of the IPs by
anti-ARF immunoblotting. mArf mutants defective for MDM2
binding (deletion of residues 8 to 32 [8–32]) or nucleolar
localization (26–37) or targeting an uncharacterized but con-
served (with human ARF) region of exon 1 (32–51, 46–51,
and L46D) were included in this analysis (Fig. 3A). Whereas
wt, 8–32, and 26–37 ARF proteins all coimmunoprecipi-
tated with CtBP (Fig. 3A, lanes 1 to 3), the L46D, 32–51, and
46–51 ARF proteins did not (Fig. 3A, lanes 4 to 6). Thus,
mArf residues between 37 and 51 or, at a minimum, 46 and 51
were required for hCtBP2 interaction, whereas the MDM2
interaction and nucleolar localization domains at the ARF N
terminus (residues 2 to 37) (3, 27, 49) were not.
As might be expected based on prior mapping of mArf
functional domains (49), loss of residues 46 to 53 or an L46D
mutation had little or no effect, whereas deletion of residues 8
to 32 of mArf rendered it unable to interact with MDM2,
localize to the nucleolus, block MDM2-dependent p53 degra-
dation, or induce G1 cell cycle arrest in mouse fibroblasts (Fig.
3B to E). Thus, mArf-CtBP interaction does not require si-
multaneous mArf-MDM2 interaction, and mutations in the
CtBP-binding region of mArf do not grossly disrupt its ability
to interact with and inhibit MDM2.
ARF induces proteasome-dependent CtBP depletion. CtBP
is reportedly degraded by the proteasome after UV exposure,
leading to apoptosis (54). Notably, the human cancer cell lines
with which CtBP degradation was observed after UV exposure
invariably expressed ARF (54), suggesting that a potential func-
tion of ARF/CtBP interaction is to induce CtBP degradation.
To more precisely define the necessity of mArf and/or p53
for CtBP degradation after UV exposure, a panel of MEFs null
for either or both p53 and mArf were screened for UV-in-
duced mouse CtBP2 (mCtBP2) degradation (Fig. 4A to D).
Cells in which mArf expression was absent (mArf/ and mArf
p53/ MEFs) did not display changes in their mCtBP2 levels
after exposure to 5 to 30 J/m2 of UV-C (Fig. 4A and B),
whereas cells retaining mArf expression (wt and p53/
MEFs) showed decreased (average of 30 to 40% reduction)
mCtBP2 levels (Fig. 4C and D). mCtBP2 degradation was
optimal after exposure to doses of UV-C in the range of 5 to
20 J/m2, but higher doses of UV did not affect mCtBP2 level,
perhaps reflecting the differential activation of signaling path-
ways that occurs at higher UV doses (20) or, more simply,
overwhelming cellular damage. Consistent with previous data
obtained from human cells, proteasome inhibition blocked
UV-induced degradation of mCtBP2 (Fig. 4E) (54). Thus,
mArf expression in mouse fibroblasts correlates with UV-in-
duced proteasome degradation of mCtBP2.
UV-induced CtBP2 degradation requires mArf/CtBP2 inter-
action. To determine if mArf/CtBP interaction was linked spe-
cifically to UV-induced CtBP degradation, mArf wt or mutant
alleles were introduced into hARF-negative U2OS cells (Fig.
5A and B). Expression of mArf sensitized U2OS cells to UV-
induced loss of hCtBP2 (optimal effect at 10 J/m2) (Fig. 5A).
Wild-type or mutant mArf alleles were then coexpressed with
GFP in U2OS cells, and transfected cells were isolated by
sorting for GFP. All mArf alleles were expressed at compara-
ble levels (Fig. 5B, top panel). Consistent with a role of ARF
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interaction in directing CtBP degradation, expression of mArf
mutants defective for hCtBP2 interaction (L46D and 46–51)
did not induce hCtBP2 loss in UV-treated cells, whereas wt
mArf or mArf(8–32), which is defective for MDM2 interac-
tion and nucleolar localization, were fully competent for di-
recting hCtBP2 degradation after UV exposure (Fig. 5B, mid-
dle panel). Thus, the ability of mArf to form a biochemical
complex with CtBP, but not its potential for MDM2 interaction
or nucleolar localization, correlated with its ability to direct
CtBP degradation.
Though ARF/CtBP2 interaction was required for UV-in-
duced CtBP2 degradation, it did not appear that the mecha-
nism of the UV effect involved specific regulation of ARF/
CtBP2 interaction. As noted in Fig. 2A, UV irradiation had no
influence on the avidity of ARF/CtBP2 interaction. Addition-
ally, CtBP2 mutated at a putative UV-regulated HIPK2 phos-
FIG. 3. The CtBP and MDM2 interaction domains of ARF are distinct. (A) (Left) ARF schematic showing MDM2 binding and nucleolar
localization (NoLS) domains and a third conserved ARF domain of unknown function with human/mouse ARF amino acid sequence alignment
(top). Conserved residues within this domain are set in boldface type. (Right) Lysates of U2OS cells transfected with wt or mutant mArf expression
plasmids were immunoprecipitated with CtBP2 antibody, followed by analysis of the IPs by anti-ARF immunoblotting. Control IP was performed
with anti-ras antibody using lysates of cells transfected with full-length mArf. (B) Mutations within the CtBP-binding region of mArf do not disrupt
MDM2 interaction. U2OS cells were transfected with the indicated mArf expression plasmids and lysates immunoprecipitated with anti-ARF
antibody (AEC40), followed by MDM2 and ARF immunoblotting. Numbers at left are molecular size markers (in kDa). vec, vector. (C) Mutations
within the CtBP-binding region of mArf do not disrupt nucleolar localization. U2OS cells were transfected with the indicated mArf expression
plasmids, and transfected cells were immunostained with ARF antibody (AEC40). All mArf alleles, except 8-32, which lacks the NoLS (amino
acids 26 to 37), properly localize to nuclear bodies consistent with the appearance of nucleoli. (D) mArf mutations within the CtBP-binding region
do not disrupt inhibition of MDM2-mediated p53 degradation. U2OS cells were transfected with HA-p53, MDM2, and the indicated mArf
expression plasmids, followed by immunoblotting of transfected cell lysates with HA and ARF antibodies. (E) Mutations within the CtBP-binding
region of mArf do not grossly disrupt induction of G1 arrest. Mouse 3T3-D1 cells (p53 wt) were transfected with the indicated mArf expression
plasmids and GFP, and cell cycle profiles of GFP-gated cells were analyzed by propidium iodide staining and FACS analysis 48 h after transfection.
A representative experiment is shown; the experiment was repeated three times with similar results.
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phorylation site (based on CtBP1 homology; S428A) (54)
bound to ARF similarly to wt CtBP2 in the presence or ab-
sence of UV (data not shown).
Human ARF causes CtBP2 depletion in the absence of
stress. To confirm that human and mouse ARF induced sim-
ilar effects on CtBP metabolism, hARF was introduced into
HCT116 colon cancer cells that were wild type or null for p53
(6) by use of a recombinant adenovirus (52). Surprisingly,
hARF expression alone, without addition of UV or other types
of stress, resulted in a profound loss of hCtBP2 that was not
seen with cells infected with a LacZ-expressing virus and that
occurred irrespective of p53 status (Fig. 5C). hCtBP1 was sim-
ilarly affected by acute expression of hARF in HCT116 p53/
cells (Fig. 5D).
The loss of CtBP after Ad-hARF infection was not influenced
by expression of adenoviral genes or signals generated by viral
entry, as hARF protein synthesized from a transfected plasmid
similarly caused CtBP depletion (Fig. 5E, second lane). However,
the link between ARF/CtBP2 interaction and CtBP2 depletion
was demonstrated by the inability of a hARF protein mutated at
the site homologous to mArf L46 [hARF(L50D)] to likewise
induce CtBP loss (Fig. 5E, third lane).
ARF destabilizes CtBP2 without affecting ubiquitination
status. To determine if the effect of exogenous ARF on
hCtBP2 was posttranscriptional, a semiquantitative reverse
transcriptase PCR analysis was performed with CtBP2-specific
primers on mRNA purified from Ad-LacZ- and Ad-hARF-
treated HCT116 p53/ cells (Fig. 5F). Despite the decreased
abundance of CtBP2 protein in hARF-expressing cells, no sig-
nificant change in CtBP2 mRNA abundance was seen, suggest-
ing that the effect of hARF on CtBP2 protein level occurred
through a posttranscriptional mechanism.
FIG. 4. UV induced CtBP degradation by the proteasome correlates with cellular ARF status. (A to D) MEFs of various mArf and p53 statuses
were exposed to increasing doses of UV-C (0 to 30 J/m2). Levels of endogenous mCtBP2 6 h after UV treatment were determined by Western
blotting. CtBP2 levels were quantitated by densitometry and normalized to a GAPDH loading control. (E) mCtBP2 is degraded by the proteasome
in response to UV. MEFs (mArf  p53) were incubated with or without proteasome inhibitor (MG132) for 24 h after mock or UV (10 J/m2)
treatment. Cell lysates were analyzed for changes in CtBP2 level by Western blotting, followed by densitometry normalized to a GAPDH
loading control. Experiments were repeated a minimum of three times with similar results, and data from representative experiments are
shown in panels A to E. Numbers below blots represent GAPDH-normalized relative levels of CtBP2.
2366 PALIWAL ET AL. MOL. CELL. BIOL.
To determine if metabolic instability of CtBP2 upon hARF
expression could account for its loss of abundance, a pulse-
chase analysis of the CtBP2 half-life was performed using
CtBP2 immunoprecipitated from [35S]methionine pulse-la-
beled HCT116 p53/ cells expressing LacZ or hARF. As seen
in Fig. 6A, the half-life of CtBP2 in LacZ-expressing cells was
indeterminately long, whereas in ARF-expressing cells, the
CtBP2 half-life was decreased to 4 h. Thus, hARF-induced
CtBP2 depletion in cells correlates with metabolic destabiliza-
tion of CtBP2.
Proteasome-mediated destabilization of CtBP2 may have
resulted from increased ubiquitination (53). The potential for
ARF to modulate CtBP2 ubiquitination was assessed by coex-
pressing CtBP2 and HA-ubiquitin in HCT116 p53/ cells,
followed by infection with Ad-LacZ or Ad-hARF. Prior to
lysis, cells were treated with MG132 proteasome inhibitor to
FIG. 5. ARF causes CtBP degradation. (A) U2OS (hARF-null) cells were transfected with vector control or full-length mArf expression
plasmids, followed by mock or UV treatment (UV-C at 0 to 30 J/m2), and CtBP2, hARF, and GAPDH levels were determined by immunoblotting
6 h after UV treatment. CtBP2 levels were quantitated by densitometry and normalized to GAPDH. (B) Degradation of endogenous CtBP by mArf
mutants. Indicated ARF expression plasmids were transfected into HCT116 p53/ cells along with pCD-GFP and treated with UV-C at 10 J/m2
24 h after transfection. Transfected cells were sorted for GFP 6 h after UV treatment, lysed, and analyzed by immunoblotting for CtBP2. CtBP2
levels were quantitated by densitometry and normalized to GAPDH. (C) hARF causes CtBP loss without stress. Lysates of HCT116 and HCT116
p53/ cells obtained 24 h postinfection with Ad-LacZ or Ad-hARF were immunoblotted with ARF, CtBP2, or GAPDH specific antibody.
(D) ARF causes CtBP1 loss. Lysates of HCT116 p53/ cells infected with Ad-LacZ or Ad-hARF, as described for panel C, were assayed for ARF,
CtBP1, and GAPDH expression by immunoblotting. (E) hARF-induced CtBP2 degradation requires an intact CtBP recognition domain. HCT116
p53/ cells were transfected with vector, hARF, or hARF(L50D) mutant expression plasmids, followed by sorting for GFP 24 h after transfection.
Cell lysates of GFP-expressing cells were analyzed by hCtBP2, GAPDH, and hARF immunoblotting. (F) hARF does not affect hCtBP2 mRNA
level. Semiquantitative (18 cycles) reverse transcriptase PCR of mRNA prepared from HCT116 p53/ cells infected with Ad-LacZ or Ad-hARF
was carried out using CtBP2 and GAPDH specific primers. Numbers below blots in panels A and B represent GAPDH-normalized relative levels
of CtBP2.
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protect ubiquitin chains from degradation and to increase the
sensitivity of ubiquitin-conjugate detection. Transfected cell
lysates were immunoprecipitated with HA antibody, and the
IPs were immunoblotted for CtBP2. As seen in Fig. 6B, no
change, or a possible decrease in the abundance of ubiquiti-
nated CtBP2, was noted upon ARF expression. Thus, destabi-
lization of CtBP2 by hARF is not accompanied by an appre-
ciable increase in CtBP2 ubiquitination, though CtBP2 is
ubiquitinated even in resting HCT116 p53/ cells.
CtBP depletion by ARF or siRNA is sufficient to trigger
p53-independent apoptosis. To determine if CtBP depletion,
as induced by ARF, could be linked to a physiologic tumor
suppression function, the effect of direct depletion of CtBP2
using siRNA was tested in cells that were wild type or null for
p53. Previous reports have indicated that, unlike mArf, hARF
can induce apoptosis in the absence of p53, though by an
undefined mechanism (17). To confirm that hARF induces
apoptosis in the absence of p53, HCT116 cells that were wt or
null for p53 were infected with Ad-hARF or Ad-LacZ; both
cell types were assayed for activation of the apoptotic program
via flow cytometric assay for cleaved caspase 3 (Fig. 7A), and
p53-null cells were also assayed for viability by use of trypan
blue exclusion (Fig. 7C). After Ad-hARF but not Ad-LacZ
infection, both cell types exhibited significant activation of
caspase 3 (20 to 23% of counted cells) (Fig. 7A), while p53-null
cells exhibited a concomitant loss of viability (Fig. 7C).
HCT116 cells (p53 wt or null) were then exposed to CtBP1,
CtBP2, or control siRNA and assayed for cleavage of caspase
3, presence of the caspase-cleaved fragment of PARP, and
viability (p53-null cells only) (Fig. 7B and C). CtBP1 or CtBP2
siRNA treatment caused a substantial loss of viability in
HCT116 p53/ cells (Fig. 7C) compared to control siRNA
treatment, suggesting that loss of CtBP expression is lethal.
Consistent with an apoptotic mechanism for cell death in CtBP
siRNA-treated cells, cleaved forms of both caspase 3 and
PARP were observed with both wild-type and p53-null
HCT116 cells treated with hCtBP1 or hCtBP2 siRNA but not
control siRNA (Fig. 7B).
Surprisingly, hCtBP1 levels were consistently decreased af-
ter hCtBP2 siRNA treatment, but not vice versa (Fig. 7B). This
may be due to a cross-reaction of hCtBP2 siRNA with hCtBP1
mRNA or direct effects of hCtBP2 on the hCtBP1 promoter
and may account for the more robust effects of hCtBP2 siRNA
on induction of caspase activity (Fig. 7B). Thus, a decrease in
CtBP1 or CtBP2 levels, either by siRNA or after ARF expres-
sion, lowers the cellular apoptotic threshold, resulting in spon-
taneous p53-independent apoptosis.
ARF-induced p53-independent apoptosis requires CtBP in-
teraction and CtBP depletion. To correlate ARF-induced apop-
tosis with the ability of ARF to degrade and deplete cellular
CtBP, CtBP2 was replaced in ARF-expressing cells with exog-
enous protein synthesized from an expression vector. HCT116
FIG. 6. ARF destabilizes CtBP2 without altering its ubiquitination. (A) hARF causes hCtBP2 destabilization. Twenty-four hours after Ad-LacZ
or Ad-hARF infection, HCT116 p53/ cells were pulse-labeled with [35S]methionine, followed by chase in unlabeled DMEM. At indicated times
during the chase, aliquots of cells were lysed and run directly on SDS-PAGE (not shown) or immunoprecipitated with anti-hCtBP2, followed by
SDS-PAGE and autoradiography. Relative hCtBP2 levels (numbers below autoradiogram) were quantitated by densitometry and normalized
against [35S]methionine incorporation as assayed for each sample by SDS-PAGE and autoradiography of total [35S]methionine-labeled proteins.
(B) Effect of hARF on CtBP2 ubiquitination. HCT116 p53/ cells were transfected with CtBP2 and HA-ubiquitin (HA-Ub) expression plasmids,
and 16 h later, transfected cells were infected with Ad-LacZ or Ad-hARF. Twenty-four hours after infection, lysates were immunoprecipitated with
anti-HA agarose, followed by CtBP2 immunoblotting. Ub-CtBP2 indicates the migration position of ubiquitinated CtBP2 species. Numbers at left
are molecular size markers (in kDa).
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p53/ cells were transfected with control vector or V5-CtBP2
expression plasmid, followed by infection with Ad-LacZ or
Ad-hARF. Twenty-four hours after infection, cells were as-
sayed for apoptosis induction by an annexin V flow cytometry
assay (Fig. 8A, left panel). Expression of ARF and CtBP2 was
confirmed by immunoblotting (Fig. 8A, right panel). Expres-
sion of CtBP in LacZ-expressing cells caused no significant
change in annexin V positivity (Fig. 8A, left panel). ARF was
potently apoptogenic, with a tripling in the fraction of apop-
totic cells (from 14% to 42%), whereas exogenous CtBP ex-
pression completely rescued cells from ARF-induced apopto-
sis, with a rate of annexin V positivity comparable to that seen
in control vector-transfected, LacZ-expressing cells (10%)
(Fig. 8A, left panel). Thus, maintenance of CtBP expression
abrogated ARF’s induction of apoptosis, suggesting that CtBP
degradation/depletion is required for ARF-induced apoptosis
in the absence of p53.
To further correlate ARF/CtBP interaction with ARF induc-
tion of p53-independent apoptosis, hARF(L50D) was com-
pared with wt hARF for the ability to induce apoptosis. Empty
vector, hARF, or hARF(L50D) expression plasmids were
transfected into HCT116 p53/ cells, and cells were analyzed
for apoptosis induction by annexin V staining (Fig. 8B, left panel).
Similar levels of expression of wt hARF and hARF(L50D) were
verified by immunoblotting (Fig. 8B, right panel). As expected,
hARF-expressing cells exhibited an increased rate of annexin V
positivity (21%), whereas hARF(L50D)-expressing cells exhibited
annexin V positivity similar to that observed for cells transfected
with empty vector (13% versus 11%) (Fig. 8B, left panel). Thus,
the ability of ARF to interact with CtBP correlates with its ability
to induce p53-independent apoptosis.
DISCUSSION
ARF exerts tumor suppression functions utilizing both p53-
dependent and -independent pathways (27, 48, 57). In this
work we have identified CtBP as a putative target for p53-
independent ARF functions, where ARF-dependent CtBP
FIG. 7. ARF expression or CtBP depletion causes p53-independent apoptosis. (A) ARF induces p53-independent apoptosis. Twenty-four hours after
infection with Ad-LacZ or Ad-hARF, HCT116 wt or p53-null cells were labeled with fluorescent caspase 3/7 substrate and propidium iodide and assayed
by FACS analysis. The percentages of live cells with active caspase 3 in each sample were plotted. A representative experiment is shown, and similar
results were seen with four separate repetitions. (B) CtBP depletion induces apoptosis. HCT116 wt or p53-null cells were treated with siRNA duplexes
complementary to either hCtBP2 or hCtBP1. Specific depletion of hCtBP1 or hCtBP2 and identification of PARP and caspase 3 cleavage products were
determined by immunoblotting. (C) hARF expression or CtBP siRNA reduces cell viability in the absence of p53. Percent viable cells, as determined by
trypan blue exclusion (mean from three independent experiments), was plotted for CtBP knockdown compared to control siRNA treatment and for
Ad-hARF infection compared to Ad-LacZ infection in HCT116 p53/ cells. Error bars indicate 1 standard deviation. scr, scrambled.
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degradation correlated with the ability of ARF to physically
interact with CtBP. ARF expression in human colon cancer
cells lacking p53 induced efficient apoptosis, as has been noted
previously (17). However, apoptosis was also observed after
CtBP knockdown alone, suggesting that CtBP lies directly
downstream of ARF in its pathway of apoptosis induction.
CtBP repletion in ARF-expressing cells via exogenous expres-
sion rescued cells from ARF-induced apoptosis, confirming a
direct role for CtBP in the apoptosis pathway activated by ARF
in the absence of p53.
The mechanism by which ARF destabilizes CtBP is unclear.
CtBP2 appeared to be constitutively ubiquitinated and unaf-
fected by ARF expression. Previous work suggests that CtBP1
ubiquitination is directly dependent on S422 phosphorylation
(S428 in CtBP2) by HIPK2 upon UV irradiation. If CtBP1 and
CtBP2 share a similar mechanism of regulation by the ubiq-
uitin system, our data would suggest that CtBP degradation
requires two steps, (i) ubiquitination and (ii) delivery to the
proteasome, which may require ARF and possibly additional
factors, such as proteasome adaptors like the human homologs
of yeast Dsk2 (hPLIC) and Rad23 (hHR23) proteins (46). We
cannot yet account for the difference between our observation
of constitutive CtBP2 ubiquitination in HCT116 cells and the
previously reported lack of CtBP1 constitutive phosphoryla-
tion in monkey COS-7 cells and MEFs. This could be due to
technical differences in phosphorylation status of the CtBP2
HIPK2 site in HCT116 cells, experimental approach, other cell
type differences, or specific differences between CtBP1 and
CtBP2. However, given that UV induces CtBP2 degradation in
MEFs only when ARF is present, we propose that CtBP deg-
radation is a two-step process (as outlined above) both in the
setting of UV-induced degradation and upon acute human
ARF expression, where the addition of UV stress is not re-
quired.
As for the identification of the CtBP E3 ubiquitin ligase, one
possibility is MDM2 itself, as it interacts with CtBP directly
(29). In this case, ARF would not target MDM2 to CtBP, as it
binds independently; this is consistent with the observed ARF-
FIG. 8. hARF-induced p53-independent apoptosis requires CtBP2 depletion and interaction. (A) CtBP2 overexpression can revert hARF-
induced apoptosis in HCT116 cells. (Left) HCT116 p53/ cells were transfected with control vector or CtBP2 expression plasmids, and 24 h later,
transfected cells were infected with Ad-LacZ or Ad-hARF. Twenty-four hours after infection, the cells were incubated with annexin V-PE along
with 7-amino-actinomycin (7-AAD) and analyzed by flow cytometry. Percentages of annexin-positive, viable (7-AAD-negative) cells are displayed.
A representative experiment is shown, and similar results were seen in three separate repetitions. (Right) Immunoblots for CtBP2, hARF, and
GAPDH expression in the transfected cells. Arrows indicate migration positions of endogenous CtBP2 and exogenous V5-CtBP2. (B) hARF/CtBP
interaction is required for the induction of apoptosis in p53-null HCT116 cells. (Left) HCT116 p53/ cells were transfected with control vector,
hARF, or L50D mutant expression plasmids, and 72 h after transfection, cells were incubated with annexin V-PE along with 7-AAD and analyzed
by flow cytometry. Percentages of annexin-positive, viable (7-AAD-negative) cells are displayed. A representative experiment is shown, and similar
results were seen in three separate repetitions. (Right) Immunoblots demonstrating CtBP2, hARF, and GAPDH expression in the transfected cells.
2370 PALIWAL ET AL. MOL. CELL. BIOL.
independent constitutive ubiquitination we have observed.
Furthermore, MDM2 has already been proposed to serve as a
proteasome delivery adaptor for p53, acting after ubiquitina-
tion. This activity of MDM2 might be related to its affinity for
the proteasome adaptor hHR23 (5). Recent reports also indi-
cate that ARF interacts with a novel hect E3 ubiquitin ligase
(mule/ARF-BP1) that can ubiquitinate both p53 and mcl-1 (8,
56). Though ARF is reported to inhibit mule/ARF-BP1 E3
activity, further investigation is warranted to determine any
possible role for this E3 in the degradation of ARF targets
such as CtBP, E2F, and B23/nucleophosmin.
Interestingly, hARF had a much more robust destabilizing
influence on CtBP than did mArf, as mArf required concom-
itant UV stress to induce CtBP degradation. This might ac-
count for the absence of a decrease in CtBP2 levels in p53/
MEFs that express mArf at constitutively high levels. Though
the CtBP binding region is well conserved between mArf and
hARF, their functional differences might be used as a tool to
investigate the mechanism of ARF-mediated CtBP degrada-
tion through generation of human/mouse ARF chimeras or
comparison of protein interaction profiles.
ARF suppresses spontaneous malignancy in mice, and it is a
frequent target for silencing in a variety of human carcinomas
(7, 13, 24, 36). The specific cell-autonomous mechanisms by
which ARF proteins suppress tumors remain unclear and may
depend on cellular and tissue contexts. Both human and mouse
ARF are associated with p53-dependent growth arrest, senes-
cence, and apoptosis due to abrogation of MDM2 repression
of p53 (47, 57). These activities are absolutely critical for sup-
pression of certain hematopoietic malignancies, such as mouse
Eu-Myc transgene-driven B-cell lymphomas and, likely, human
T-cell acute lymphoblastic leukemia (12, 14, 37, 43).
However, ARF suppression of epithelial tumors in mice is,
at least in part, p53 independent, and the mechanism is un-
known (24). Our results and previous work (15, 54) suggest
that CtBP maintains a certain antiapoptotic “tone” in cells
through repression of proapoptotic gene transcription. Such
repression might be abrogated via ARF-induced CtBP degra-
dation, resulting in derepression of such genes. Preliminary
data suggest that among apoptosis-specific genes analyzed with
a transcription array, the BH3-only protein Bik was upregu-
lated upon either CtBP knockdown or ARF expression (S.
Pande, S. Paliwal, and S. R. Grossman, unpublished data).
Specific loss of ARF has been linked to tumor invasiveness
and metastasis in a mouse skin cancer model (24). Notably, an
antiapoptotic survival signal(s) is necessary for tumor cells to
escape their normal microenvironment, invade, and metasta-
size (1, 45). Suppression of tumor invasion and metastasis by
ARF, especially in a setting of p53 inactivation, might there-
fore ultimately be explained by its ability to induce apoptosis
through the inhibitory targeting of CtBP. This model of ARF
tumor suppression also suggests the idea that, as a tumor
suppressor target, CtBP might act as an oncogene if its expres-
sion or activity was dysregulated in cancer cells. Further study
of the ARF-CtBP axis in mouse and human cancer will likely
yield important insights into mechanisms of tumor progression
and provide leads for the therapeutic targeting of this pathway
in those tumors where it is dysregulated.
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